Skip to main content

Critical Advances in Bronchiectasis Treatment and the Foundational Role of

Neutrophil-Mediated Inflammation in NCFBE

Reducing Exacerbations, Improving FEV₁, and Optimizing Quality of Life with Brensocatib at the Front Lines of Bronchiectasis Care—A Year 2026 Clinical Success Update for NCFBE

FEATURED AUTHORITIES ON BRONCHIECTASIS
Click on Speaker to View Their iQ&A Sessions

Professor James Chalmers

Professor James Chalmers

Professor (Clinical), Molecular and Clinical Medicine

School of Medicine

University of Dundee School of Medicine

Dundee, Scotland, United Kingdom

Prof. Francesco Blasi, MD, FERS

Prof. Francesco Blasi, MD, FERS

Professor of Respiratory Medicine

Department of Pathophysiology and Transplantation,

Vice Rector for Relations with the National Health Service

University of Milan

Dean of the School of Medicine, University of Milan

Milan, Italy

Professor David E. Griffith, MD

Professor David E. Griffith, MD

Professor of Medicine

National Jewish Health

Denver, Colorado, USA

Professor Michael Loebinger, MA, FRCP, PhD

Professor Michael Loebinger, MA, FRCP, PhD

Director of the Lung Division, Clinical Director of Laboratory Medicine,

Consultant Respiratory Medicine,

Royal Brompton & Harefield Hospitals

Professor of Practice (Respiratory Medicine),

London, United Kingdom

Anne E. O’Donnell, MD

Anne E. O’Donnell, MD

The Nehemiah and Naomi Cohen Chair in Pulmonary Disease Research

Professor of Medicine

Chief, Division of Pulmonary, Critical Care and Sleep Medicine

Georgetown University Medical Center/Medstar Georgetown University Hospital

Washington, DC, USA

Professor Kevin Winthrop, MD, MPH

Professor Kevin Winthrop, MD, MPH

Professor of Infectious Diseases, Ophthalmology,

Professor of Public Health and Preventive Medicine

Division of Infectious Diseases, OHSU

Oregon Health and Sciences University

Portland, Oregon, USA

ACCESS RESOURCES AND TRIALS
IN BRONCHIECTASIS

ABOUT THIS PROGRAM AND FACULTY DISCLOSURES

Latest Videos |view all videos

Can you discuss the current burden of NCFBE for patients and the healthcare system, in general, especially in regions globally—U.S., Europe, and Japan—where we see high disease burden, increasing prevalence, and profoundly impaired quality of life?

Can you discuss the current burden of NCFBE for patients and the healthcare system, in general, especially in regions globally—U.S., Europe, and Japan—where we see high disease burden, increasing prevalence, and profoundly impaired quality of life?

Professor Chalmers, can you share your focus on new therapeutic strategies for non-CF bronchiectasis and what key topics you’ll address in the iQ&A Bronchiectasis Pulmonary Medicine Intelligence Zone?

Professor Chalmers, can you share your focus on new therapeutic strategies for non-CF bronchiectasis and what key topics you’ll address in the iQ&A Bronchiectasis Pulmonary Medicine Intelligence Zone?

Can you explain the role of neutrophil serine proteases in NCFBE inflammation and how DPP-1 inhibition with brensocatib reduces NSP activity, mitigating progressive pulmonary inflammation?

Can you explain the role of neutrophil serine proteases in NCFBE inflammation and how DPP-1 inhibition with brensocatib reduces NSP activity, mitigating progressive pulmonary inflammation?

Given brensocatib’s recognition as a breakthrough in NCFBE care, how do you envision its role in current management and its integration into near-future treatment strategies for this progressive condition?

Given brensocatib’s recognition as a breakthrough in NCFBE care, how do you envision its role in current management and its integration into near-future treatment strategies for this progressive condition?

Before discussing WILLOW and ASPEN, what clinical biomarkers and symptomatic endpoints were prioritized to fully assess brensocatib’s efficacy, disease-modifying potential, and impact on quality of life?

Before discussing WILLOW and ASPEN, what clinical biomarkers and symptomatic endpoints were prioritized to fully assess brensocatib’s efficacy, disease-modifying potential, and impact on quality of life?

Can you outline the Phase 2 WILLOW trial design and results for brensocatib in NCFBE, including key efficacy and safety endpoints? Did the study demonstrate improvements in quality of life for participants?

Can you outline the Phase 2 WILLOW trial design and results for brensocatib in NCFBE, including key efficacy and safety endpoints? Did the study demonstrate improvements in quality of life for participants?

Are we entering a new therapeutic era for NCFBE with agents like brensocatib, recently approved to target neutrophil-driven inflammation central to the disease’s pathobiology?

Are we entering a new therapeutic era for NCFBE with agents like brensocatib, recently approved to target neutrophil-driven inflammation central to the disease’s pathobiology?

Based on WILLOW results in NCFBE, which positive signals—fewer exacerbations, better quality of life, reduced antibiotic use—did you aim to further evaluate and expand upon in the Phase 3 ASPEN trial?

Based on WILLOW results in NCFBE, which positive signals—fewer exacerbations, better quality of life, reduced antibiotic use—did you aim to further evaluate and expand upon in the Phase 3 ASPEN trial?

Given NCFBE’s heterogeneity and global prevalence, what are its key etiologies—particularly chronic infection—and how does recognizing these factors enhance detection, treatment, and confirmation of this severe pulmonary condition?

Given NCFBE’s heterogeneity and global prevalence, what are its key etiologies—particularly chronic infection—and how does recognizing these factors enhance detection, treatment, and confirmation of this severe pulmonary condition?